Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Fineline Cube Mar 11, 2026
Company Deals Drug

AstraZeneca Initiates CLARITY-Gastric 02 Phase III – Sonesitatug Vedotin Combo Triggers $45 Million Milestone from KYM Biosciences

Fineline Cube Mar 11, 2026
Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Fineline Cube Mar 11, 2026
Company Drug

Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia

Fineline Cube Mar 11, 2026
Company

PharmaBlock Expands US Presence with New R&D Facility in West Chester

Fineline Cube Mar 28, 2023

PharmaBlock, a leading company based in Nanjing (SHE: 300725), has announced the opening of a...

Company Drug

CSPC Pharmaceutical Receives NMPA Approval for Generic Otezla Equivalent

Fineline Cube Mar 28, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Celgene’s...

Policy / Regulatory

NMPA Introduces Procedures to Adjust Chemical Generic Reference Preparations

Fineline Cube Mar 28, 2023

The National Medical Products Administration (NMPA) has released a document outlining procedures for the adjustment...

Company Deals

BJ Bioscience Partners with MSD for Phase I Clinical Trial of BJ-001 and Keytruda

Fineline Cube Mar 28, 2023

Shanghai-based biotech BJ Bioscience Inc. has announced a clinical trial collaboration and supply agreement with...

Company Medical Device

Acotec Scientific’s Vericor Receives Marketing Approval from Thailand FDA

Fineline Cube Mar 28, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval...

Company Drug

CANbridge Pharmaceuticals Completes Enrollment in Phase II GBM Trial for CAN008

Fineline Cube Mar 28, 2023

Sino-US biopharma CANbridge Pharmaceuticals (HKG: 1228) has announced the completion of patient enrollment in a...

Company Drug

Chongqing Genrix’s Xeligekimab for Psoriasis Accepted for Market Approval Review

Fineline Cube Mar 28, 2023

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that the market approval filing...

Company

Hansoh Pharmaceutical Reports 2022 Revenues and Highlights Growth in Innovative Drugs

Fineline Cube Mar 28, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has released its financial report for 2022....

Policy / Regulatory

National ADR Monitoring Report Highlights Oncology Drugs and Elderly Patient Safety

Fineline Cube Mar 28, 2023

The National Center for ADR Monitoring has published its “National Adverse Drug Reaction Monitoring Annual...

Policy / Regulatory

China’s New Internet Advertising Regulations Impact Pharmaceutical Sector

Fineline Cube Mar 28, 2023

The State Administration for Market Regulation has released the latest version of the “Measures for...

Company

Fosun Pharma Reports 12.66% YOY Revenue Growth and Increased R&D Investment in 2022 Financial Report

Fineline Cube Mar 28, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report...

Company Drug

CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China

Fineline Cube Mar 27, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has obtained an Emergency...

Company Medical Device

Boston Scientific Launches Athletis Peripheral Balloon Dilatation Catheter in China

Fineline Cube Mar 27, 2023

US-based medical device leader, Boston Scientific Corporation (NYSE: BSX), has announced the market launch of...

Policy / Regulatory

CDE Launches Technical Guidelines for Pediatric Anti-tumor Drug Development

Fineline Cube Mar 27, 2023

The Center for Drug Evaluation (CDE) has released a set of Technical Guidelines focused on...

Company Deals

Huarun Pharmaceutical Co., Ltd Announces Private Placement to Fund Expansion and R&D

Fineline Cube Mar 27, 2023

China-based Huaren Pharmaceutical Co., Ltd (SHE: 300110) is set to raise capital through the private...

Policy / Regulatory

CDE Issues New Guidance on Pre-Phase III Clinical Trial Meetings for Innovative Drugs

Fineline Cube Mar 27, 2023

The Center for Drug Evaluation (CDE) has released the “Innovative Chemical Drug Pre-Phase III Clinical...

Company Deals

Zhaoke Ophthalmology Signs Distribution Agreement with Kwangdong for NVK002 in South Korea

Fineline Cube Mar 27, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Company Drug

Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Gain Clinical Trial Approvals

Fineline Cube Mar 27, 2023

China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu...

Company Deals

YHLO Biotech Partners with NCRCID to Develop Advanced Tuberculosis Diagnostics

Fineline Cube Mar 27, 2023

China-based Shenzhen YHLO Biotech Co., Ltd has entered into a strategic partnership with the National...

Company Deals

Everest Medicines Receives $280 Million from Gilead’s Immunomedics Following Partnership Cancellation

Fineline Cube Mar 27, 2023

China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront...

Posts pagination

1 … 512 513 514 … 633

Recent updates

  • Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029
  • J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer
  • Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia
  • Zelgen’s Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up
  • Fosun Pharma’s Tenapanor (Vteglea) Issues First China Prescription – NHE3 Inhibitor Targets Hyperphosphatemia in Dialysis Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Company Drug

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Company Drug

Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia

Company Drug

Zelgen’s Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.